Criteria for the administration of systemic antimicotic therapy in surgical intensive care units (literature review)
暂无分享,去创建一个
[1] J. Timsit,et al. The current treatment landscape: candidiasis. , 2016, The Journal of antimicrobial chemotherapy.
[2] J. Sobel,et al. Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] R. Schmid,et al. Fungal “colonisation” is Associated with Increased Mortality in Medical Intensive Care Unit Patients with Liver Cirrhosis , 2015, Mycopathologia.
[4] M. Bassetti,et al. An Italian consensus for invasive candidiasis management (ITALIC) , 2014, Infection.
[5] Nicolas Papon,et al. Emerging and Emerged Pathogenic Candida Species: Beyond the Candida albicans Paradigm , 2013, PLoS pathogens.
[6] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] T. Calandra,et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[8] F. Grenouillet,et al. Candida spp. with Acquired Echinocandin Resistance, France, 2004–2010 , 2012, Emerging infectious diseases.
[9] J. Vincent,et al. European expert opinion on the management of invasive candidiasis in adults. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[10] Jacques Bille,et al. Diagnosis of invasive candidiasis in the ICU , 2011, Annals of intensive care.
[11] R. Bellomo,et al. Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality , 2011, Critical care.
[12] J. Perfect,et al. Early treatment of candidemia in adults: a review. , 2011, Medical mycology.
[13] J. Sobel,et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit , 2011, Mycoses.
[14] R. Drew,et al. Echinocandin pharmacodynamics: review and clinical implications. , 2010, The Journal of antimicrobial chemotherapy.
[15] Jordi Rello,et al. International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.
[16] J. Rello,et al. Temporal trends, risk factors and outcomes in albicans and non-albicans candidaemia: an international epidemiological study in four multidisciplinary intensive care units. , 2009, International journal of antimicrobial agents.
[17] M. Ghannoum,et al. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[18] J. Nolla,et al. Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study , 2009, European Journal of Clinical Microbiology & Infectious Diseases.
[19] M. Ellis. New dosing strategies for liposomal amphotericin B in high-risk patients. , 2008, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[20] R. Hay,et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] M. Falagas,et al. Candida Albicans Versus Non-Albicans Intensive Care Unit-Acquired Bloodstream Infections: Differences in Risk Factors and Outcome , 2008, Anesthesia and analgesia.
[22] C. d’Enfert,et al. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome , 2008, Intensive Care Medicine.
[23] K. Garey,et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] M. Falagas,et al. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies , 2006, European Journal of Clinical Microbiology and Infectious Diseases.
[25] Shane Gillespie,et al. Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] J. Devlin,et al. Temporal assessment of Candida risk factors in the surgical intensive care unit. , 2001, Archives of surgery.
[27] H. Moecke,et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients , 1997, Intensive Care Medicine.
[28] R. Auckenthaler,et al. Candida Colonization and Subsequent Infections in Critically III Surgical Patients , 1994, Annals of surgery.
[29] J. Perfect,et al. Resistance to Antifungal Agents: Mechanisms and Clinical Impact , 2008 .
[30] R. Barnes. Early diagnosis of fungal infection in immunocompromised patients. , 2008, The Journal of antimicrobial chemotherapy.